Related Experiment Video
Updated: Apr 23, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Treatment algorithm in 2014 for advanced non-small cell lung cancer: therapy selection by tumour histology and
1Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Visiting Professor Medical University of Bialystok, Bialystok, Poland.
Abstract:
The availability of antineoplastic monoclonal antibodies, small molecules and newer cytotoxics such as pemetrexed, the EGFR-tyrosine kinase inhibitors erlotinib, gefitinib, afatinib as well as the anti-angiogenic bevacizumab and the ALK-inhibitor crizotinib has recently changes the treatment algorithm of advanced non-small cell lung cancer. Decision making in 2014 is characterized by customizing therapy, by selecting a specific therapeutic regimen based on the histotype and the genotype of the tumour. This refers to first-line induction therapy and maintenance therapy as well, but also to subsequent lines of therapy since anti-neoplastic drugs and regimens used upfront clinically influence the selection of agents/regimes considered for second-/third-line treatment. Consequently, therapy customization through tumour histology and molecular markers has significantly influenced the work of pathologists around the globe and the process of obtaining an extended therapeutically relevant tumour diagnosis. Not only histological sub-typing became standard but molecular information is also considered of increasing importance for treatment selection. Routine molecular testing in certified laboratories must be established, and the diagnostic process should ideally be performed under the guidance of evidence based recommendation. The process of investigating and implementing medical targeting in lung cancer therefore, requires advanced diagnostic techniques and expertise and because of its large dimension is costly and influenced by the limitation of financial and clinical resources.
Insights
Advanced non-small cell lung cancer treatment now involves personalized therapy based on tumor type and genetic makeup. This requires precise diagnostics and impacts subsequent treatment choices, highlighting the need for molecular testing.
Area of Science:
- Oncology
- Molecular Diagnostics
- Cancer Therapeutics
Background:
- Recent advancements in antineoplastic agents, including monoclonal antibodies, small molecules, and targeted therapies like EGFR-tyrosine kinase inhibitors and ALK-inhibitors, have transformed advanced non-small cell lung cancer treatment.
- The 2014 treatment landscape emphasizes personalized therapeutic strategies tailored to tumor histotype and genotype.
Purpose of the Study:
- To highlight the shift towards customized therapy in advanced non-small cell lung cancer.
- To underscore the critical role of tumor histology and molecular markers in guiding treatment decisions.
- To emphasize the evolving demands on pathology services for accurate and therapeutically relevant diagnoses.
Main Methods:
- Review of current treatment algorithms for advanced non-small cell lung cancer.
- Analysis of the impact of novel antineoplastic agents on therapeutic decision-making.
- Discussion of the integration of molecular testing into routine diagnostics.
Main Results:
- Therapeutic decision-making is now characterized by customization based on histotype and genotype for all lines of therapy.
- The selection of agents for subsequent treatment lines is influenced by upfront therapeutic regimens.
- Tumor histology and molecular markers are increasingly crucial for treatment selection, influencing pathology workflows.
Conclusions:
- Personalized therapy based on tumor characteristics is the standard for advanced non-small cell lung cancer.
- Routine molecular testing in certified laboratories, guided by evidence-based recommendations, is essential.
- Implementing targeted therapies requires advanced diagnostic techniques, expertise, and consideration of resource limitations.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...